Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

Home > Formulary : Adult > Covid-19 >

BNSSG Adult Joint Formulary

COVID-19 related prescribing guidance

Checked: not set yet by Next Review: not set yet

General Advice on Medicines and COVID-19

General Medicines-Related Issues

Teamnet COVID-19 Resources for Practices

Please click here for PSNC summary of updates and guidance relating to community pharmacy and COVID-19

Please click here for University of Liverpool COVID-19 drug interaction checker tool

Please click here for Primary Care advice for immunosuppression in COVID-19 patients

Yellow Card Reporting

The MHRA have launched a dedicated Yellow Card reporting site for healthcare products that are used in Coronavirus (COVID-19) treatment to be easily reported:

Healthcare professionals, patients and carers are asked to report all suspected side effects to medicines or medical device adverse incidents related to COVID-19 treatment. This also includes medicines that patients and healthcare professionals are using off-label to treat COVID-19. Reporting will enable the MHRA to rapidly identify new and emerging side effects and medical device issues which may not have been previously known about, including diagnostic tests for COVID-19. This includes any medicines taken by patients to manage long-term, or pre-existing conditions that may influence the disease or have any potential interactions.


High Risk Drug Monitoring

The Covid-19 High Risk Drug Monitoring Guidance has now been withdrawn as it is now appropriate to return use of Shared Care Protocols for monitoring guidance. This decision is supported by UHBW, NBT and AWP. 


Sick Day Rules

Please click here for BNSSG guidance on sick day rules (preventing dehydration during periods of acute illness)


Gastro-intestinal system

Inflammatory Bowel Disease

Please click here for advice from International Organization for the study of Inflammatory Bowel Disease during the COVID-19 outbreak.

Please click here for patient advice from Crohn's and Colitis UK during the COVID-19 outbreak.

Please click here for advice from British Society of Gastroenterology on use of immunosuppression during the COVID-19 outbreak.

Please click here for NICE COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response.


Cardiovascular System


Please click here for the NHSE advice regarding anticoagulation during the COVID-19 outbreak

Please see BNSSG COVID-19: Coagulopathy, Thrombosis prevention and DIC


Respiratory System

Please click here for information, guidance and resources from the British Thoracic Society (BTS) to support the respiratory community during the COVID-19 pandemic


Central Nervous System


The Association of British Neurologists hosts guidance on COVID-19 for people with neurological conditions. Please click here for ABN Guidelines on Covid-19.



Please click here for CAS alert for the NHSE message regarding use of ibuprofen during the COVID-19 outbreak. (14/4/2020)

Please click here for NICE evidence summary on the use of ibuprofen during the COVID-19 outbreak (14/4/20) 


Mental Health

Please click here to visit Avon and Wiltshire Mental Health Partnership (AWP) website for further information


Sodium Valproate

The MHRA have provided temporary advice for the 'Valproate Pregnancy Prevention Programme' during the Coronavirus (COVID-19) pandemic - available here


Malignant Disease and Immunosuppression


Please click here for COVID-19 guidance from British Society of Rheumatology

Please click here for guidance on management of patients on corticosteroids.

This guidance links to the Society of Endocrinology's advice on managing adrenal crisis during COVID-19


Renal Disease

Please click here for patient advice from Kidney Care UK during the COVID-19 outbreak.


Systemic Anti-cancer treatments

Please click here for NICE rapid guideline on delivery of systemic anticancer treatments during COVID-19 outbreak.